文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

高危前列腺癌雄激素抑制联合大分割盆腔放疗的急性和晚期毒性

Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy.
PubMed 文献 · Pract Radiat Oncol · 2017-01-20

该研究报告105例高危前列腺癌患者接受雄激素剥夺治疗(ADT)联合前列腺及淋巴结区中度大分割放疗(HypoRT)的急性和晚期毒性。方案为前列腺60 Gy/20次、淋巴结区44 Gy/20次,同步推量调强放疗,中位随访41个月。≥2级急性胃肠和泌尿毒性均为17%,晚期≥2级胃肠和泌尿毒性分别为7%和8%,无4-5级毒性。48个月无进展生存率82%。结论认为该方案可行且耐受良好。

要点

  • 前列腺60 Gy/20次、淋巴结44 Gy/20次同步推量调强放疗方案可行。
  • ≥2级急性胃肠和泌尿毒性均为17%,仅少数3级。
  • 晚期≥2级胃肠和泌尿毒性分别为7%和8%,无4-5级毒性。

核心结论

  • ADT联合中度大分割放疗(前列腺60 Gy、淋巴结44 Gy,均20次)同步推量调强放疗在高危前列腺癌患者中可行且耐受良好。

主要发现

  • 急性≥2级胃肠毒性18例(17%),泌尿毒性19例(17%),仅1例和3例发生急性3级胃肠或泌尿毒性。
  • 晚期≥2级胃肠毒性7例(7%),泌尿毒性8例(8%),无4级或5级毒性。
  • 末次随访时2级胃肠和泌尿毒性分别为5%和3%,无残留≥3级毒性。
  • 48个月 actuarial 无进展生存率为82%。

关键数值与推荐

  • 放疗剂量:前列腺60 Gy/20次(4周),淋巴结区44 Gy/20次,同步推量调强放疗。
  • ADT于放疗前2-3个月开始,中位持续时间18个月。
  • 毒性按CTCAE v3前瞻性评估。

临床怎么用

  • 该中度大分割同步推量方案可缩短治疗 duration,对患者和医疗系统便利,结果支持开展随机试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report acute and late toxicity rates in patients with high-risk prostate cancer treated with androgen deprivation therapy (ADT) and moderate hypofractionated radiation therapy (HypoRT) to the prostate and nodal areas. METHODS AND MATERIALS: Patients with localized, high-risk prostate cancer were treated with a HypoRT regimen of 60 Gy in 20 fractions (4 weeks) to the prostate volume while the nodal areas received 44 Gy in the same 20 fractions delivered with intensity modulated RT with a simultaneous integrated boost technique. ADT started 2 to 3 months before HypoRT and was given to all patients. Acute and late toxicity were prospectively assessed and graded according to the Common Terminology Criteria for Adverse Events, version 3. RESULTS: A total of 105 patients treated between September 2010 and November 2013 were reviewed. Median follow-up was 41 months, with 97% of patients followed for more than 26 months. Median ADT duration was 18 months. Acute grade 2 or higher gastrointestinal (GI) or genitourinary (GU) toxicity was seen in 18 (17%) and 19 (17%) patients, respectively, with only 1 and 3 patients experiencing either a GI or GU acute grade 3 toxicity. The worst grade 2 or higher late GI and GU toxicity were seen in 7 (7%) and 8 (8%) patients, respectively. There was no grade 4 or 5 toxicity. At the last follow-up, the rate of grade 2 GI and GU toxicity was 5% and 3%, respectively, with no residual grade ≥3 toxicity. The 48-month actuarial progression free survival is 82%. CONCLUSIONS: ADT with moderate HypoRT delivered with IMRT and an integrated simultaneous boost to the prostate (60 Gy) and pelvic nodes (44 Gy) in 20 fractions is feasible and well tolerated. This approach shortens treatment duration and is convenient for patients and the health system, and its results support a randomized trial.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Faria S, Ruo R, Cury F, et al. Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy. Pract Radiat Oncol. 2017. PMID: 28222995. doi:10.1016/j.prro.2017.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。